Related Experiment Video
Updated: Dec 27, 2025
12:52
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
16.3K
Glial TIM-3 Modulates Immune Responses in the Brain Tumor Microenvironment
Hyung-Seok Kim1,2, Chi Young Chang2, Hee Jung Yoon2
1Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang-si Gyeonggi-do, Republic of Korea.
Cancer Research
|February 26, 2020
Summary
Glial TIM-3 plays a distinct role in the brain tumor microenvironment, influencing immune responses differently than T-cell TIM-3. This finding highlights glial TIM-3 as a potential target for glioblastoma immunotherapy.
Area of Science:
- Immunology
- Neuro-oncology
- Molecular Biology
Background:
- T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) is a known immune checkpoint, often studied in T cells.
- Its role in the brain tumor microenvironment, particularly in glial cells, is not well understood.
- Understanding TIM-3's context-dependent functions is crucial for developing effective cancer immunotherapies.
Purpose of the Study:
- To investigate the specific functional characteristics of TIM-3 in glial cells within the brain tumor microenvironment.
- To determine how TIM-3 expression and function in glia differ from T cells in glioma models.
- To explore the immunoregulatory roles of glial TIM-3 in glioblastoma.
Main Methods:
- Utilized an orthotopic mouse glioma model to analyze TIM-3 expression in tumor cells, glia, and T cells.
- Compared TIM-3 expression patterns in tumor-infiltrating versus contralateral glial and T cells.
- Employed TIM-3 mutant and inducible mice to assess TIM-3's impact on immune-associated molecule expression (iNOS, PD-L1) in glia.
- Investigated TIM-3's cross-regulation with TLR2 and TLR4 in glia exposed to brain tumor conditioned media.
- Assessed IFNγ production in T cells co-cultured with TIM-3-defective versus normal glia.
Main Results:
- TIM-3 expression varied in glia and T cells within the brain tumor microenvironment, distinct from other immune checkpoints.
- TIM-3 expression was lower in tumor-infiltrating microglia/macrophages (CD11b+CD45mid) but higher in CD8+ T cells.
- TIM-3 influenced the expression of iNOS and PD-L1 in glia and was cross-regulated by TLR2, not TLR4.
- T cells co-cultured with TIM-3-deficient glia showed reduced IFNγ production.
Conclusions:
- Glial TIM-3 exhibits distinct properties and actively responds to the brain tumor microenvironment.
- TIM-3 in glia plays unique intracellular and intercellular immunoregulatory roles, differing from its function in T cells.
- These findings suggest glial TIM-3 as a novel target for glioblastoma immunotherapy, particularly concerning myeloid cell responses.
